Table 2 New drug prescribing on patient level.
From: Is new drug prescribing in primary care specialist induced?
Salmeterol/fluticasone | |||
|---|---|---|---|
New drug N (%) | Reference drug N (%) | Relative Rate (95% CI) | |
Medical specialist | 103 (60.2%) | 302 (16.9%) | 3.56 (3.03–4.17) |
GP | 68 (39.8%) | 1,481 (83.1%) | Ref. |
Rofecoxib | |||
Medical specialist | 137 (23.0%) | 1,445 (13.0%) | 1.77 (1.51–2.06) |
GP | 459 (77.0%) | 9,656 (87.0%) | Ref. |
Esomeprazole | |||
Medical specialist | 53 (34.9%) | 424 (19.6%) | 1.78 (1.41–2.25) |
GP | 99 (65.1%) | 1,741 (80.4%) | Ref. |
Tiotropium | |||
Medical specialist | 293 (52.7%) | 123 (14.5%) | 3.64 (3.03–4.36) |
GP | 263 (47.3%) | 726 (85.5%) | Ref. |
Rosuvastatin | |||
Medical specialist | 89 (42.0%) | 355 (39.5%) | 1.06 (0.89–1.27) |
GP | 123 (58.0%) | 544 (60.5%) | Ref. |
Overall | |||
Medical specialist | 675 (40.0%) | 2,649 (15.8%) | 2.53 (2.37–2.71) |
GP | 1,012 (60.0%) | 14,148 (84.2%) | Ref. |